| Title |
Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, January 2012
|
| DOI | 10.2147/dmso.s15404 |
| Pubmed ID | |
| Authors |
J Uy, L Fogelfeld, Y Guerra |
| Abstract |
We have now at our disposal the new rapid-acting insulin analogs, of which insulin lispro was the first to become commercially available. While the differences in pharmacokinetic and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these changes have not been as clear. In the present review, we discuss the structure, pharmacology, and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are compared with those of insulin regular and other insulin analogs in different clinical situations. Also included are the aspects of quality of life and cost-effectiveness that may modify the modern practitioner's decision to adopt one type of insulin over another. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 6% |
| Belgium | 1 | 3% |
| Unknown | 30 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 18% |
| Researcher | 5 | 15% |
| Student > Bachelor | 4 | 12% |
| Student > Doctoral Student | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 9 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Nursing and Health Professions | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Computer Science | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 9 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2012.
All research outputs
#17,348,916
of 25,457,297 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#611
of 1,184 outputs
Outputs of similar age
#172,814
of 250,438 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#4
of 7 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,438 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.